Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oxford BioMedica plc (OXBDF)
OTHER OTC:OXBDF
Holding OXBDF?
Track your performance easily
OXBDF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.02 - $5.95
Previous Close$5.28
Volume2.00
Average Volume (3M)8.36K
Market Cap
$554.47M
Enterprise Value$560.23M
Total Cash (Recent Filing)£141.28M
Total Debt (Recent Filing)£114.28M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Sep 23, 2024EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding105,359,856
10 Day Avg. Volume479
30 Day Avg. Volume8,363
Standard Deviation0.16
R-Squared0.16
Alpha-0.00653
Financial Highlights & Ratios
Price to Book (P/B)3.32
Price to Sales (P/S)3.65
Price to Cash Flow (P/CF)-40.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.65Price Target Upside22.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Oxford BioMedica News
PremiumCompany Announcements
Oxford Biomedica Strengthens Board with Key Appointment
PremiumCompany Announcements
Oxford BioMedica to Present at Healthcare ConferencePremiumCompany Announcements
Oxford Biomedica Grants Share Options to Key Personnel
PremiumCompany Announcements
Oxford Biomedica Announces Total Voting Rights Update
PremiumCompany Announcements
Oxford BioMedica Sees Shift in Voting Rights
PremiumCompany Announcements
Oxford Biomedica Seeks Stock Market Expansion
PremiumCompany Announcements
Oxford Biomedica Executives Granted Share OptionsOptions Prices
Currently, No data available
---
Ownership Overview
<0.01% Insiders
0.25% Mutual Funds
2.15% Other Institutional Investors
97.50% Public Companies and
Individual Investors
OXBDF FAQ
What was Oxford BioMedica plc’s price range in the past 12 months?
Oxford BioMedica plc lowest stock price was $2.02 and its highest was $5.95 in the past 12 months.
What is Oxford BioMedica plc’s market cap?
Currently, no data Available
When is Oxford BioMedica plc’s upcoming earnings report date?
Oxford BioMedica plc’s upcoming earnings report date is Sep 23, 2024 which is 60 days ago.
How were Oxford BioMedica plc’s earnings last quarter?
Oxford BioMedica plc released its earnings results on Apr 29, 2024. The company reported -$1.439 earnings per share for the quarter, missing the consensus estimate of -$0.624 by -$0.815.
Is Oxford BioMedica plc overvalued?
According to Wall Street analysts Oxford BioMedica plc’s price is currently Undervalued.
Does Oxford BioMedica plc pay dividends?
Oxford BioMedica plc does not currently pay dividends.
What is Oxford BioMedica plc’s EPS estimate?
Oxford BioMedica plc’s EPS estimate is -$0.36.
How many shares outstanding does Oxford BioMedica plc have?
Oxford BioMedica plc has 105,923,080 shares outstanding.
What happened to Oxford BioMedica plc’s price movement after its last earnings report?
Oxford BioMedica plc reported an EPS of -$1.439 in its last earnings report, missing expectations of -$0.624. Following the earnings report the stock price went down -1.639%.
Which hedge fund is a major shareholder of Oxford BioMedica plc?
Currently, no hedge funds are holding shares in OXBDF
---
Oxford BioMedica Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.65 (22.91% Upside)
$6.65 (22.91% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
113.56%
12-Months-Change
Fundamentals
Return on Equity
-117.88%
Trailing 12-Months
Asset Growth
-39.27%
Trailing 12-Months
Company Description
Oxford BioMedica plc
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The firm also provides bioprocessing and process development services to third parties. It operates through the Platform and Product segment. The Platform segment consists of the revenue generating bioprocessing and process development activities undertaken for third parties. The Product segment includes clinical and preclinical development of in vivo and ex vivo gene and cell therapy products which are owned by the group. The company was founded by Alan J. Kingsman and Susan M. Kingsman in 1996 and is headquartered in Oxford, the United Kingdom.
---
OXBDF Company Deck
---
OXBDF Earnings Call
Q2 2024
0:00 / 0:00
---
OXBDF Stock 12 Month Forecast
Average Price Target
$6.65
▲(22.91% Upside)
Technical Analysis
Advaxis
―
TRACON Pharmaceuticals
―
Cyclacel Pharmaceuticals
―
Armata Pharmaceuticals
―
Best Analysts Covering OXBDF
1 Year
1 Year Success Rate
8/19 ratings generated profit
1 Year Average Return
+3.97%
reiterated a buy rating 2 months ago
Copying Charles Weston's trades and holding each position for 1 Year would result in 42.11% of your transactions generating a profit, with an average return of +3.97% per trade.
---